Clinical Study to Begin upon approval of IRB for Clinical Phase
PETACH TIKVA, Israel, June 17, 2015 /PRNewswire/ —
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), today announced that its wholly owned subsidiary, One World Cannabis Ltd. (“the Company”), an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, is proud to announce it has received the first basic science study (lab) results on the effect of several combination of Cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma cell line RPMI8226.
Based on the results, One World Cannabis will submit the clinical trial protocol to the IRB (Helsinki committee). The company expects to receive institutional review board approval for the study within 6-9 weeks.
The OWC multiple myeloma study was done by three repetitive tests on the effect of cannabis extract with various combination ratios of THC/CBD and pure THC and CBD (50% concentration). The results present more than 60% malignant cell death. More results of pure THC and CBD are under further analysis.
Multiple myeloma cells were cultured for 48 hours with CBD and THC (all cannabis extracts) as compare to their combinations – CBD: THC 1:1; CBD: THC 5:1 and CBD: THC 1:5. Combination Index (CI) value <1, =1, >1 indicates synergism, additive effect, and antagonism, respectively. Each treatment was performed in triplicate in four independent experiments and presented as mean. The treatment of CBD in combination with THC had synergistic effect, being their cytotoxic effect is higher with each of the three combinations tested.
CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner.
Multiple myeloma, a cancer of plasma cells in the bone marrow, accounts for 10% of all hematologic malignancies. It is the second most common hematologic cancer and represents 1% of all cancer diagnoses and 2% of all cancer deaths.
The basic science phase of the study has begun several weeks ago, at the Sheba Academic Medical Center (affiliated with Tel-Aviv University). Dr. Merav Leiba, Head of Sheba’s Multiple Myeloma Service and Multiple Myeloma Research Lab is leading the study. The company conducts the study in accordance with Sheba’s Internal Review Board (IRB) approval.
“If further studies will prove this concept, we plan to conduct a clinical study which will explore these combinations in multiple myeloma patients. In addition, most multiple myeloma patients suffer from a devastating bone disease. Since cannabinoid receptors have also been found on bone cells, we hypothesize that the combination of CBD and THC may alleviate myeloma bone disease,” said Dr. Leiba.
In view of the basic study results OWC has begun the development of a unique formulation that includes cannabis extracts for a new delivery system in the form of a cannabis dissoluble tablet to treat multiple myeloma. The cannabis dissoluble tablet will provide physicians with the ability to control and administrate optimal dosage. This can be treated with every multiple myeloma patient and will replace the common usage of medical cannabis today which is not acceptable by scientists and physicians as smoking, edibles and oil extracts with no substantial dosage control.
“We founded this company to research and develop new medical solution from cannabis for targeted medical conditions to benefit the quality of lives of patients. Those first results are exceeding our expectations, and we hope to be able to achieve the same success in the clinical phase. Only then we can assert that we are on the way to a new cannabis medicine to treat multiple myeloma cancer and save patients’ lives,” said Dr. Baruch, OWC Director of Research and Regulatory Affairs.
About One World Cannabis Ltd.
One World Cannabis Ltd. (“the Company”) is an Israel-based company founded in 2014 by a group of professionals with expertise in the field of medical cannabis (marijuana) treatment and medical cannabis regulatory affairs. The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB: OWCP).
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
5W Public Relations
SOURCE OWC Pharmaceutical Research Corp.